Amylyx Pharmaceuticals (AMLX) Assets Average (2022 - 2026)

Amylyx Pharmaceuticals has reported Assets Average for 5 years, with the latest figure at $279.1 million in Q2 2026.

• On a quarterly basis, Assets Average rose 34.73% year-over-year to $279.1 million in Q2 2026; TTM through Jun 2026 was $279.1 million, a 34.73% increase from a year earlier, with the FY2025 full-year figure at $263.1 million, down 25.99% from the prior year.
• Assets Average was $279.1 million for Q2 2026 at Amylyx Pharmaceuticals, down from $313.1 million in the prior quarter.
• The five-year high for Assets Average was $492.0 million in Q4 2023, with the low at $190.0 million in Q1 2022.
• Average Assets Average over 5 years is $316.7 million, with a median of $288.9 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Assets Average surged 126.26% in 2023, then sank 55.79% in 2025.
• Over 5 years, Assets Average stood at $286.4 million in 2022, then soared by 71.77% to $492.0 million in 2023, then sank by 54.84% to $222.2 million in 2024, then surged by 56.5% to $347.7 million in 2025, then fell by 19.73% to $279.1 million in 2026.
• The last three Assets Average figures came in at $279.1 million (Q2 2026), $313.1 million (Q1 2026), and $347.7 million (Q4 2025), per Business Quant data.